Reviva Pharmaceuticals Holdings, Inc. Accounts Payable
Reviva Pharmaceuticals Holdings, Inc. (RVPH) had Accounts Payable of $2.46 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-12
- 2026-06-30: Accounts Payable, Current $2.46M.
- 2026-03-31: Accounts Payable, Current $2.09M.
- 2025-12-31: Accounts Payable, Current $3.01M.
- 2025-09-30: Accounts Payable, Current $5.43M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $2.46M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $2.09M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $3.01M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $5.43M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $4.97M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $4.72M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $6.28M 10-K · filed 2026-03-30 |
| 2024-09-30 | $8.78M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $4.69M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $5.72M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $3.85M 10-K · filed 2025-04-03 |
| 2023-09-30 | $5.28M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $2.65M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $2.86M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $3.52M 10-K · filed 2024-04-15 |
| 2022-09-30 | $2.35M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $2.55M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $1.43M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $509.58K 10-K · filed 2023-03-30 |
| 2021-09-30 | $420.78K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $358.26K 10-Q · filed 2021-08-16 |
| 2021-03-31 | $471.30K 10-Q · filed 2021-05-17 |
| 2020-12-31 | $1.01M 10-K · filed 2022-03-15 |
| 2020-11-30 | $859.80K 10-Q · filed 2021-01-14 |
| 2020-08-31 | $736.44K 10-Q · filed 2020-10-14 |
| 2020-05-31 | $501.26K 10-Q · filed 2020-07-07 |
| 2020-02-29 | $299.65K 10-Q · filed 2021-01-14 |
| 2019-12-31 | $224.54K 10-K/A · filed 2021-05-07 |
| 2019-11-30 | $100.10K 10-Q · filed 2020-01-10 |
| 2019-08-31 | $33.93K 10-Q · filed 2019-10-08 |
| 2019-05-31 | $27.68K 10-Q · filed 2019-07-03 |
| 2019-02-28 | $23.05K 10-K · filed 2020-05-04 |
| 2018-11-30 | $22.40K 10-Q · filed 2019-01-09 |
| 2018-08-31 | $1.52K 10-Q · filed 2018-10-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |